Showing 1101-1110 of 5062 results for "".
- Biologics Most Likely to Be Continued After MACE: Studyhttps://practicaldermatology.com/news/biologics-most-likely-to-be-continued-after-mace-study/2483287/Biologic therapies were linked with greater treatment persistence than non-biologic systemic agents or phototherapy among patients with psoriasis who experience major adverse cardiovascular events (MACE), according to findings from a retrospective study of Korean n
- Analysis Links NHR With Increased Risk of PsOhttps://practicaldermatology.com/news/analysis-links-nhr-with-increased-risk-of-pso/2483261/The neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) is independently associated with an increased risk of psoriasis, raising the possibility of a novel biomarker for risk stratification, according to a large cross-sectional analysis of US adults published in Frontiers in Immuno
- Study: Tralokinumab Demonstrates Durable Response, High Retention in AD Patientshttps://practicaldermatology.com/news/tralokinumab-shows-strong-one-year-results-in-real-world-ad-study/2483171/The long-term use of tralokinumab in adults with moderate-to-severe atopic dermatitis (AD). Over a 52-week period, the IL-13 inhibitor demonstrated clinically meaningful and sustained improvements across multiple outcome measures, with a favorable safety profile and
- Analysis: Global Prevalence of Hidradenitis Suppurativa Higher Than Previously Estimatedhttps://practicaldermatology.com/news/analysis-global-prevalence-of-hidradenitis-suppurativa-higher-than-previously-estimated/2483148/The estimate of the global prevalence of hidradenitis suppurativa (HS) sits at 0.99%, which notably higher than prior global figures, according to a new analysis. The research team compiled data from 25 population-based studies
- HS Patients on Adalimumab Face Higher Risk of Serious Infections than PsO Counterpartshttps://practicaldermatology.com/news/hs-patients-on-adalimumab-face-higher-risk-of-serious-infections-than-pso-counterparts/2483028/Patients with hidradenitis suppurativa (HS) initiating adalimumab face a significantly higher risk of serious, noncutaneous infections requiring hospitalization compared with patients with psoriasis, a new cohort study finds.
- FDA Speeds Development of Hair Loss Drug Rezpegaldesleukinhttps://practicaldermatology.com/news/fda-speeds-development-of-nektars-autoimmune-hair-loss-drug/2475953/The FDA has granted Fast Track designation to the investigational biologic rezpegaldesleukin (Nektar Therapeutics) for the treatment of severe-to-very severe alopecia areata (AA) in adults and adolescents aged 12 and older who weigh at least 40 kg.
- OSkin Study: Genetic Risk and Nevus Count Stronger Predictors for NAMhttps://practicaldermatology.com/news/genetic-risk-and-nevus-count-stronger-predictors-for-nam-study-finds/2475635/High nevus density and polygenic susceptibility are more strongly associated with nevus-associated melanoma (NAM) than with de novo melanoma, according to results from a new large-scale, population-based cohort study. The QSk
- Positive Early Results in Tralokinumab Trial for AD on Handshttps://practicaldermatology.com/news/Positive-Early-Results-Tralokinumab-Trial-AD-Hands/2475575/A trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) on the hands, who are candidates for systemic therapy, met the primary endpoint and all secondary endpoints with a statistically significant improvement in AD on the hands after 16 weeks of
- Study: Sofpironium Gel Effective for Axillary Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-support-sofpironium-gel-for-axillary-hyperhidrosis/2475489/Sofpironium topical gel, 12.45%, showed efficacy and tolerability in treating primary axillary hyperhidrosis, according to pooled results from two pivotal Phase 3 trials. Researchers for the combined analysis of the Cardigan
- VISIBLE: Guselkumab Provides Scalp Psoriasis Relief in Diverse Skin Toneshttps://practicaldermatology.com/news/visible-guselkumab-provides-scalp-psoriasis-relief-in-diverse-skin-tones/2475455/Guselkumab 100 mg demonstrated efficacy and sustained improvement through 48 weeks in a cohort of adults with moderate to severe scalp psoriasis and skin of color, new research suggests. In the B cohort of the phase 3b, rand